R9156

Raltitrexed

≥98% (HPLC), solid

• 同義詞: L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl), ICI-D-1694, ZD-1694
• 經驗公式（希爾表示法）: C₂₁H₂₂N₄O₆S
• CAS號碼: 112887-68-0
• 分子量：: 458.49
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329824044
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: solid
• 顏色: off-white to light yellow
• 溶解度: H₂O: ≥10 mg/mL; DMSO: ≥40 mg/mL
• 起源: AstraZeneca
• 儲存溫度: 2-8°C
• SMILES 字串: O=C1NC(C)=NC2=C1C=C(CN(C3=CC=C(C(N[C@H](CCC(O)=O)C(O)=O)=O)S3)C)C=C2

描述

生化／生理作用

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives.

Raltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.

特點和優勢

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全資訊

• 象形圖: GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H300,H360
• 防範說明: P201 - P301 + P310 + P330
• 危險分類: Acute Tox. 2 Oral - Repr. 1B
• 儲存類別代碼: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable
• 個人防護裝備: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges